Imunon, INC Form 4 insider transactions

Michael H Tardugno, Executive Chairman of Board and a Director of Imunon, Inc., received 7,169 shares of common stock on September 25, 2026.

Douglas Vincent Faller, Chief Medical Officer of Imunon, Inc., received 4,390 shares of common stock on September 25, 2026.

Michael H Tardugno, Executive Chairman of Board and a Director of Imunon, Inc., received 5,824 shares of common stock on September 11, 2026.

Stacy Lindborg, President and CEO and a Director of Imunon, Inc., received 5,504 shares of common stock on September 11, 2026.

Douglas Vincent Faller, Chief Medical Officer of Imunon, Inc., received 4,211 shares of common stock on September 11, 2026.

Michael H Tardugno, Executive Chairman of Board and a Director of Imunon, Inc., received 7,371 shares of common stock on August 28, 2026.

Stacy Lindborg, President and CEO and a Director of Imunon, Inc., received 6,822 shares of common stock on August 28, 2026.

Stacy Lindborg, President and CEO and a Director of Imunon, Inc., received 6,615 shares of common stock on August 14, 2026.

Douglas Vincent Faller, Chief Medical Officer of Imunon, Inc., received 3,516 shares of common stock on August 14, 2026.

Michael H Tardugno, Executive Chairman of Board and a Director of Imunon, Inc., received 7,147 shares of common stock on August 14, 2026.

Susan Eylward, General Counsel and Corp Sec of Imunon, Inc., sold 2,449 shares of common stock on August 14, 2026 for $1.63 per share.

Frederick J. Fritz, a Director of Imunon, Inc., received 6,934 shares of common stock on July 31, 2026.

Susan Eylward, General Counsel and Corp Sec of Imunon, Inc., sold 2,541 shares of common stock on July 31, 2026 for $1.57 per share.

Douglas Vincent Faller, Chief Medical Officer of Imunon, Inc., received 3,649 shares of common stock on July 31, 2026.

Stacy Lindborg, President and CEO and a Director of Imunon, Inc., received 5,010 shares of common stock on July 31, 2026.

Michael H Tardugno, Executive Chairman of Board and a Director of Imunon, Inc., received 4,603 shares of common stock on July 17, 2026.

Susan Eylward, General Counsel and Corp Sec of Imunon, Inc., sold 2,150 shares of common stock on July 17, 2026 for $1.78 per share.

Douglas Vincent Faller, Chief Medical Officer of Imunon, Inc., received 3,082 shares of common stock on July 17, 2026.

Stacy Lindborg, President and CEO and a Director of Imunon, Inc., received 4,907 shares of common stock on July 17, 2026.

Imunon, Inc. reports that Executive Chairman Michael H. Tardugno acquired 4,410 shares of common stock on July 2, 2026, valued at $1.91 per share, as compensation for services.

Susan Eylward, General Counsel and Corp Sec of Imunon, Inc., reported transactions involving common stock, including stock granted in lieu of salary.

Imunon, Inc. reports that Chief Medical Officer Douglas Vincent Faller acquired 1,308 shares of common stock on July 2, 2026, valued at $1.91 per share, as part of a stock grant in lieu of cash for a portion of his base salary.

Stacy Lindborg, President and CEO of Imunon, Inc., acquired 2,534 shares of common stock on July 2, 2026, valued at $1.91 per share, as part of her compensation.

Imunon, Inc. reports a stock grant to Chief Medical Officer Douglas Faller, issued in lieu of a cash bonus.

Imunon, Inc. reports a stock grant to General Counsel Susan Eylward and subsequent sale of shares.

Michael H. Tardugno, Executive Chairman of Imunon, Inc., acquired 42,519 shares of common stock on June 25, 2026, in lieu of a cash bonus.

Stacy Lindborg, President and CEO of Imunon, Inc., acquired 67,150 shares of common stock on June 25, 2026, valued at $1.72 per share, as part of her 2025 annual bonus.

Executive Chairman Michael H. Tardugno acquired 4,089 shares of Imunon, Inc. common stock as compensation in lieu of cash salary.

Stacy Lindborg, President and CEO of Imunon, Inc., acquired 1,593 shares of common stock on June 5, 2026, valued at $2.06 per share, as part of a stock grant in lieu of cash for salary.

Michael H. Tardugno, Executive Chairman of Imunon, Inc., reported a transaction involving the acquisition of 3,484 shares of common stock on May 22, 2026, at a price of $2.2 per share.